<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587351</url>
  </required_header>
  <id_info>
    <org_study_id>1512M81981</org_study_id>
    <nct_id>NCT02587351</nct_id>
  </id_info>
  <brief_title>Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Beta-Blockers for the Prevention of Acute Exacerbations of COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that&#xD;
      will enroll 1028 patients with at least moderately severe COPD over a three year period and&#xD;
      follow them at regular intervals for one year. The primary endpoint is time to first acute&#xD;
      exacerbation. Secondary endpoints include rates and severity of COPD exacerbations,&#xD;
      cardiovascular events, all-cause mortality, lung function, dyspnea, quality of life and&#xD;
      metoprolol-related side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis The primary hypothesis is that metoprolol succinate will reduce the risk of COPD&#xD;
      exacerbations as compared to placebo. The secondary hypothesis is that metoprolol succinate&#xD;
      will not adversely impact lung function, exercise tolerance, dyspnea or quality of life as&#xD;
      compared to placebo.&#xD;
&#xD;
      Study Flow Patients will be screened and then randomized over a 2 week period and will then&#xD;
      undergo a dose titration period for the following six weeks. Thereafter patients will be&#xD;
      followed for 42 additional weeks on their target dose of metoprolol or placebo followed by a&#xD;
      4 week washout period.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      Primary: To determine the effect of once daily metoprolol succinate compared with placebo on&#xD;
      the time to first exacerbation in moderate to severe COPD patients who are prone to&#xD;
      exacerbations and who do not have absolute indications for beta-blocker therapy.&#xD;
&#xD;
      Secondary: To estimate the effect of metoprolol succinate compared with placebo on:&#xD;
&#xD;
        1. The rate and severity of COPD exacerbations over 12 months&#xD;
&#xD;
        2. Incidence and severity of metoprolol-related side effects including those that require&#xD;
           cessation of drug&#xD;
&#xD;
        3. Lung function as assessed by spirometry, dyspnea as assessed by the Modified Medical&#xD;
           Research Council Scale (MMRC) and San Diego Shortness of Breath Questionnaire, exercise&#xD;
           tolerance as measured by six minute walk test (6MWD), and quality of life as assessed by&#xD;
           the Short Form 36, St. Georges Respiratory Questionnaire (SGRQ) and COPD Assessment Test&#xD;
           (CAT) and Personal HEART Score.&#xD;
&#xD;
        4. Hospitalizations&#xD;
&#xD;
        5. The rate of major adverse cardiovascular events (MACE) (defined by cardiovascular death,&#xD;
           hospitalization for myocardial infarction, heart failure, or stroke), percutaneous&#xD;
           coronary intervention or coronary artery bypass grafting&#xD;
&#xD;
        6. All-cause mortality&#xD;
&#xD;
      Secondary subgroup analyses for 1) cardiovascular risk based on Personal HEART Score and 2)&#xD;
      age greater versus less than 65.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility&#xD;
  </why_stopped>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Occurrence of an Acute COPS Exacerbation</measure>
    <time_frame>1 year</time_frame>
    <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Exacerbations of COPD</measure>
    <time_frame>1 year</time_frame>
    <description>Number of acute exacerbations of COPD - rate per person-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Department Visits Resulting From Acute Exacerbations of COPD</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Emergency Department visits resulting from acute exacerbations of COPD - rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Admissions Resulting From Acute Exacerbations of COPD</measure>
    <time_frame>1 year</time_frame>
    <description>Number of hospital admissions resulting from acute exacerbations of COPD - rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Days Resulting From Acute Exacerbations of COPD</measure>
    <time_frame>14 months</time_frame>
    <description>Number of hospital days resulting from acute exacerbations of COPD reported as negative binomial estimates of mean hospital days per patient year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiovascular events (MACE), percutaneous coronary intervention or coronary artery bypass grafting. MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Presumed Metoprolol-related Side-effects</measure>
    <time_frame>1 year</time_frame>
    <description>New or worsened (Neural: depression, headache, syncope, seizures, somnolence, memory loss, loss of sexual desire or erectile dysfunction, and fatigue; Hypersensitivity: rash, pruritus, tongue or facial swelling; Gastrointestinal: diarrhea, vomiting, nausea or constipation; Cardiovascular: bradycardia and hypotension as discussed below; Respiratory: bronchospasm and changes in lung function as discussed below).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Medical Research Council Dyspnea Scale (MMRC)</measure>
    <time_frame>1 year</time_frame>
    <description>Modified Medical Research Council Dyspnea Scale (MMRC) change from baseline to visit day 336. The MMRC scale is a five-point scale originally published in 1959 that considers certain activities, such as walking or climbing stairs, which provoke breathlessness. Scale from 0 to 4 with lower scores indicating less breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>1 year</time_frame>
    <description>Change in FEV1 % Predicted from baseline to visit day 336 as assessed by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity as Assessed by the 6 Minute Walk Distance (6MWD)</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>6MWD change from baseline to visit day 336. The 6MWD has been used as a simple tool to assess overall exercise tolerance in patients with chronic cardiopulmonary disease including COPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Systemic Inflammation</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>Fibrinogen: assessed at screening/randomization and at conclusion of the study to determine if beta-blockade impacts levels of systemic inflammation that portend overall cardiac risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>SGRQ change from baseline to visit day 336. The SGRQ total score change from baseline. SGRQ is a respiratory specific health status questionnaire with scores ranging from 0 to 100. The lower score indicates a better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test (CAT)</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>COPD Assessment Test (CAT) change from baseline. The CAT is a simple, eight item, health status instrument for patients with COPD that provides a score of 0-40. Lower scores denote better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>San Diego Shortness of Breath Questionnaire (SOBQ)</measure>
    <time_frame>1 year</time_frame>
    <description>San Diego Shortness of Breath Questionnaire (SOBQ) change from baseline. A 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. Each item has a 6-point scale (0 = &quot;not at all&quot; to 5 = &quot;maximal or unable to do because of breathlessness&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbations of COPD and MACE</measure>
    <time_frame>12 months</time_frame>
    <description>MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Physical Function Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. 8 multi-item scales with higher score indicating better health state. The Physical Functioning scale is 10 items assessing the extent to which health limits physical activities such as self-care, walking, climbing stairs, bending lifting, and moderate and vigorous activities transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Role Functioning - Physical Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Physical Scale contains 4 items assessing the extent to which physical health interferes with work or other daily activities, including accomplished less than wanted, limitations in the kind of activities. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Role Functioning - Emotional Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Emotional Scale includes 3 items assessing extent to which emotional problems interfere with work or other daily activities. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Energy/Fatigue Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Energy/Fatigue Scale includes 4 items. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Emotional Well-being Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Emotional Well-being Scale includes 5 items assessing emotional wellbeing. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Social Functioning Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Social Functioning Scale includes 2 items assessing extent to which physical health or emotional problems interfere with normal social activities. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) Bodily Pain Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Bodily Pain Scale includes 2 items assessing the intensity of pain and effect of pain on normal work, both inside and outside the house. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-36) General Health Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The General Health Scale includes 4 items assessing personal evaluations of health. Items are transformed to a score with a range of 0-100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">532</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate</intervention_name>
    <description>Extended release Metoprolol succinate</description>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <other_name>Metoprolol Succinate ER</other_name>
    <other_name>Toprol XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects, â‰¥ 40 and less than 85 years of age&#xD;
&#xD;
          2. Clinical diagnosis of at least moderate COPD as defined by the Global Initiative for&#xD;
             Obstructive Lung Disease (GOLD) criteria (53):&#xD;
&#xD;
               -  Post bronchodilator FEV1/FVC &lt; 70% (Forced expiratory volume in 1 second/ forced&#xD;
                  vital capacity),&#xD;
&#xD;
               -  Post bronchodilator FEV1 &lt; 80% predicted, with or without chronic symptoms (i.e.,&#xD;
                  cough, sputum production).&#xD;
&#xD;
          3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active&#xD;
             smokers.&#xD;
&#xD;
          4. To enrich the population for patients who are more likely to have acute exacerbations&#xD;
             (54), each subject must meet one or more of the following 4 conditions:&#xD;
&#xD;
               -  Have a history of receiving a course of systemic corticosteroids and/or&#xD;
                  antibiotics for respiratory problems in the past year,&#xD;
&#xD;
               -  Visiting an Emergency Department for a COPD exacerbation within the past year, or&#xD;
&#xD;
               -  Being hospitalized for a COPD exacerbation within the past year&#xD;
&#xD;
               -  Be using or be prescribed supplemental oxygen for 12 or more hours per day&#xD;
&#xD;
               -  Willingness to make return visits and availability by telephone for duration of&#xD;
                  study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of asthma established by each study investigator on the basis of the&#xD;
             recent American Thoracic Society/European Respiratory Society and National Institute&#xD;
             for Health and Care Excellence guidelines.&#xD;
&#xD;
          2. The presence of a diagnosis other than COPD that results in the patient being either&#xD;
             medically unstable, or having a predicted life expectancy &lt; 2 years.&#xD;
&#xD;
          3. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who&#xD;
             refuse to use acceptable birth control (hormone-based oral or barrier contraceptive)&#xD;
             for the duration of the study.&#xD;
&#xD;
          4. Current tachy or brady arrhythmias requiring treatment&#xD;
&#xD;
          5. Presence of a pacemaker and/or internal cardioverter/defibrillator&#xD;
&#xD;
          6. Patients with a history of second or third degree (complete) heart block, or sick&#xD;
             sinus syndrome&#xD;
&#xD;
          7. Baseline EKG revealing left bundle branch block, bifascicular block, ventricular&#xD;
             tachyarrhythmia, atrial fibrillation, atrial flutter, supraventricular tachycardia&#xD;
             (other than sinus tachycardia and multifocal atrial tachycardia), or heart block (2nd&#xD;
             degree or complete)&#xD;
&#xD;
          8. Resting heart rate less than 65 beats per minute, or sustained resting tachycardia&#xD;
             defined as heart rate greater than 120 beats per minute.&#xD;
&#xD;
          9. Resting systolic blood pressure of less than 100mm Hg.&#xD;
&#xD;
         10. Subjects with absolute (Class 1) indications for beta-blocker treatment as defined by&#xD;
             the combined American College of Cardiology Foundation/American Heart Association Task&#xD;
             Force on Practice Guidelines, and the American College of Physicians, American&#xD;
             Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association,&#xD;
             Society for Cardiovascular Angiography and Interventions, and Society of Thoracic&#xD;
             Surgeons Guidelines which include myocardial infarction, acute coronary syndrome,&#xD;
             percutaneous coronary intervention or coronary artery bypass surgery within the prior&#xD;
             3 years and patients with known congestive heart failure defined as left ventricular&#xD;
             ejection fraction &lt;40%.(29, 30)&#xD;
&#xD;
         11. Critical ischemia related to peripheral arterial disease.&#xD;
&#xD;
         12. Other diseases that are known to be triggered by beta-blockers or beta-blocker&#xD;
             withdrawal including myasthenia gravis, periodic hypokalemic paralysis,&#xD;
             pheochromocytoma, and thyrotoxicosis&#xD;
&#xD;
         13. Patients on other cardiac medications known to cause atrioventricular (AV) node&#xD;
             conduction delays such as amiodarone, digoxin, and calcium channel blockers including&#xD;
             verapamil and diltiazem as well as patients taking clonidine.&#xD;
&#xD;
         14. Hospitalization for uncontrolled diabetes mellitus or hypoglycemia within the last 12&#xD;
             months.&#xD;
&#xD;
         15. Patients with cirrhosis&#xD;
&#xD;
         16. A clinical diagnosis of bronchiectasis defined as production of &gt; one-half cup of&#xD;
             purulent sputum/day.&#xD;
&#xD;
         17. Patients otherwise meeting the inclusion criteria will not be enrolled until they are&#xD;
             a minimum of four weeks from their most recent acute exacerbation (i.e., they will not&#xD;
             have received a course of systemic corticosteroids, an increased dose of chronically&#xD;
             administered systemic corticosteroids, and/or antibiotics for an acute exacerbation&#xD;
             for a minimum of four weeks).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Dransfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Connett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Lazarus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham, Alabama VA Medical</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco-Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA BioMed at Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical &amp; Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian/Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14853</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-4701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Lung function</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Beta blockers</keyword>
  <keyword>Metoprolol succinate</keyword>
  <keyword>Smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02587351/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metoprolol Succinate</title>
          <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoprolol Succinate</title>
          <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="268"/>
            <count group_id="B2" value="264"/>
            <count group_id="B3" value="532"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="7.6"/>
                    <measurement group_id="B2" value="64.8" spread="7.9"/>
                    <measurement group_id="B3" value="65.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 after bronchodilation - % of predicted value</title>
          <units>% of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="16.3"/>
                    <measurement group_id="B2" value="40.8" spread="16.2"/>
                    <measurement group_id="B3" value="41.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1:FVC ratio - %</title>
          <units>ratio %</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="11.7"/>
                    <measurement group_id="B2" value="45.2" spread="21.6"/>
                    <measurement group_id="B3" value="44.7" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history No. of pack-yr</title>
          <units>pack-years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="28.7"/>
                    <measurement group_id="B2" value="49.5" spread="29.6"/>
                    <measurement group_id="B3" value="50.1" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood pressure - mm Hg</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128.4" spread="16.5"/>
                    <measurement group_id="B2" value="130.6" spread="15.9"/>
                    <measurement group_id="B3" value="129.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood pressure - mm Hg</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.2" spread="9.2"/>
                    <measurement group_id="B2" value="76.8" spread="9.1"/>
                    <measurement group_id="B3" value="77.0" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Occurrence of an Acute COPS Exacerbation</title>
        <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days&quot;.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of an Acute COPS Exacerbation</title>
          <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness requiring treatment with antibiotics and/or systemic steroids for at least three days&quot;.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" lower_limit="162" upper_limit="282"/>
                    <measurement group_id="O2" value="222" lower_limit="189" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Acute Exacerbations of COPD</title>
        <description>Number of acute exacerbations of COPD - rate per person-year</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Exacerbations of COPD</title>
          <description>Number of acute exacerbations of COPD - rate per person-year</description>
          <units>no. of events/person-yr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" lower_limit="1.21" upper_limit="1.61"/>
                    <measurement group_id="O2" value="1.33" lower_limit="1.15" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Emergency Department Visits Resulting From Acute Exacerbations of COPD</title>
        <description>Number of Emergency Department visits resulting from acute exacerbations of COPD - rate</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Emergency Department Visits Resulting From Acute Exacerbations of COPD</title>
          <description>Number of Emergency Department visits resulting from acute exacerbations of COPD - rate</description>
          <units>events per person-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.11" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.12" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital Admissions Resulting From Acute Exacerbations of COPD</title>
        <description>Number of hospital admissions resulting from acute exacerbations of COPD - rate</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital Admissions Resulting From Acute Exacerbations of COPD</title>
          <description>Number of hospital admissions resulting from acute exacerbations of COPD - rate</description>
          <units>events per person-year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.47" upper_limit="0.86"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.30" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Days Resulting From Acute Exacerbations of COPD</title>
        <description>Number of hospital days resulting from acute exacerbations of COPD reported as negative binomial estimates of mean hospital days per patient year.</description>
        <time_frame>14 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Days Resulting From Acute Exacerbations of COPD</title>
          <description>Number of hospital days resulting from acute exacerbations of COPD reported as negative binomial estimates of mean hospital days per patient year.</description>
          <units>hospital days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="2.05" upper_limit="4.64"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.62" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiovascular Events</title>
        <description>Major adverse cardiovascular events (MACE), percutaneous coronary intervention or coronary artery bypass grafting. MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiovascular Events</title>
          <description>Major adverse cardiovascular events (MACE), percutaneous coronary intervention or coronary artery bypass grafting. MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden Cardiac Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>All-cause mortality count</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>All-cause mortality count</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Presumed Metoprolol-related Side-effects</title>
        <description>New or worsened (Neural: depression, headache, syncope, seizures, somnolence, memory loss, loss of sexual desire or erectile dysfunction, and fatigue; Hypersensitivity: rash, pruritus, tongue or facial swelling; Gastrointestinal: diarrhea, vomiting, nausea or constipation; Cardiovascular: bradycardia and hypotension as discussed below; Respiratory: bronchospasm and changes in lung function as discussed below).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Presumed Metoprolol-related Side-effects</title>
          <description>New or worsened (Neural: depression, headache, syncope, seizures, somnolence, memory loss, loss of sexual desire or erectile dysfunction, and fatigue; Hypersensitivity: rash, pruritus, tongue or facial swelling; Gastrointestinal: diarrhea, vomiting, nausea or constipation; Cardiovascular: bradycardia and hypotension as discussed below; Respiratory: bronchospasm and changes in lung function as discussed below).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fainting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of sexual desire or erectile dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of energy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tongue or facial swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of breath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest tightness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart skipping or irregular beats</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness/light headedness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Medical Research Council Dyspnea Scale (MMRC)</title>
        <description>Modified Medical Research Council Dyspnea Scale (MMRC) change from baseline to visit day 336. The MMRC scale is a five-point scale originally published in 1959 that considers certain activities, such as walking or climbing stairs, which provoke breathlessness. Scale from 0 to 4 with lower scores indicating less breathlessness.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Medical Research Council Dyspnea Scale (MMRC)</title>
          <description>Modified Medical Research Council Dyspnea Scale (MMRC) change from baseline to visit day 336. The MMRC scale is a five-point scale originally published in 1959 that considers certain activities, such as walking or climbing stairs, which provoke breathlessness. Scale from 0 to 4 with lower scores indicating less breathlessness.</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change in FEV1 % Predicted from baseline to visit day 336 as assessed by spirometry</description>
        <time_frame>1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change in FEV1 % Predicted from baseline to visit day 336 as assessed by spirometry</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" lower_limit="-3.28" upper_limit="-1.20"/>
                    <measurement group_id="O2" value="-1.46" lower_limit="-2.50" upper_limit="-0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Capacity as Assessed by the 6 Minute Walk Distance (6MWD)</title>
        <description>6MWD change from baseline to visit day 336. The 6MWD has been used as a simple tool to assess overall exercise tolerance in patients with chronic cardiopulmonary disease including COPD.</description>
        <time_frame>Baseline, 1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Capacity as Assessed by the 6 Minute Walk Distance (6MWD)</title>
          <description>6MWD change from baseline to visit day 336. The 6MWD has been used as a simple tool to assess overall exercise tolerance in patients with chronic cardiopulmonary disease including COPD.</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.64" lower_limit="-28.75" upper_limit="-6.53"/>
                    <measurement group_id="O2" value="-11.87" lower_limit="-23.21" upper_limit="-0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Systemic Inflammation</title>
        <description>Fibrinogen: assessed at screening/randomization and at conclusion of the study to determine if beta-blockade impacts levels of systemic inflammation that portend overall cardiac risk.</description>
        <time_frame>Baseline, 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Systemic Inflammation</title>
          <description>Fibrinogen: assessed at screening/randomization and at conclusion of the study to determine if beta-blockade impacts levels of systemic inflammation that portend overall cardiac risk.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fibrinogen baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.8" spread="94.6"/>
                    <measurement group_id="O2" value="378.2" spread="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen Visit 336</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.5" spread="90.5"/>
                    <measurement group_id="O2" value="386.0" spread="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ)</title>
        <description>SGRQ change from baseline to visit day 336. The SGRQ total score change from baseline. SGRQ is a respiratory specific health status questionnaire with scores ranging from 0 to 100. The lower score indicates a better health status.</description>
        <time_frame>Baseline, 1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ)</title>
          <description>SGRQ change from baseline to visit day 336. The SGRQ total score change from baseline. SGRQ is a respiratory specific health status questionnaire with scores ranging from 0 to 100. The lower score indicates a better health status.</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="-1.01" upper_limit="2.04"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-1.79" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Assessment Test (CAT)</title>
        <description>COPD Assessment Test (CAT) change from baseline. The CAT is a simple, eight item, health status instrument for patients with COPD that provides a score of 0-40. Lower scores denote better health status.</description>
        <time_frame>Baseline, 1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Assessment Test (CAT)</title>
          <description>COPD Assessment Test (CAT) change from baseline. The CAT is a simple, eight item, health status instrument for patients with COPD that provides a score of 0-40. Lower scores denote better health status.</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.07" upper_limit="1.69"/>
                    <measurement group_id="O2" value="-0.59" lower_limit="-1.41" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>San Diego Shortness of Breath Questionnaire (SOBQ)</title>
        <description>San Diego Shortness of Breath Questionnaire (SOBQ) change from baseline. A 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. Each item has a 6-point scale (0 = &quot;not at all&quot; to 5 = &quot;maximal or unable to do because of breathlessness&quot;).</description>
        <time_frame>1 year</time_frame>
        <population>Participants with data at baseline and visit day 336</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>San Diego Shortness of Breath Questionnaire (SOBQ)</title>
          <description>San Diego Shortness of Breath Questionnaire (SOBQ) change from baseline. A 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. Each item has a 6-point scale (0 = &quot;not at all&quot; to 5 = &quot;maximal or unable to do because of breathlessness&quot;).</description>
          <population>Participants with data at baseline and visit day 336</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="-1.01" upper_limit="2.04"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-1.79" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Exacerbations of COPD and MACE</title>
        <description>MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Exacerbations of COPD and MACE</title>
          <description>MACE defined by cardiovascular death, hospitalization for myocardial infarction, heart failure, or stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden cardiac death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD Exacerbation (Serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Physical Function Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. 8 multi-item scales with higher score indicating better health state. The Physical Functioning scale is 10 items assessing the extent to which health limits physical activities such as self-care, walking, climbing stairs, bending lifting, and moderate and vigorous activities transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Physical Function Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. 8 multi-item scales with higher score indicating better health state. The Physical Functioning scale is 10 items assessing the extent to which health limits physical activities such as self-care, walking, climbing stairs, bending lifting, and moderate and vigorous activities transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="15.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="15.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="15.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="35.0" lower_limit="15.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Role Functioning - Physical Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Physical Scale contains 4 items assessing the extent to which physical health interferes with work or other daily activities, including accomplished less than wanted, limitations in the kind of activities. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Role Functioning - Physical Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Physical Scale contains 4 items assessing the extent to which physical health interferes with work or other daily activities, including accomplished less than wanted, limitations in the kind of activities. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="0.0" upper_limit="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="0.0" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="0.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="0.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Role Functioning - Emotional Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Emotional Scale includes 3 items assessing extent to which emotional problems interfere with work or other daily activities. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Role Functioning - Emotional Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Role Functioning - Emotional Scale includes 3 items assessing extent to which emotional problems interfere with work or other daily activities. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Energy/Fatigue Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Energy/Fatigue Scale includes 4 items. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Energy/Fatigue Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Energy/Fatigue Scale includes 4 items. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="35.0" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="45.0" lower_limit="30.0" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="45.0" lower_limit="30.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Emotional Well-being Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Emotional Well-being Scale includes 5 items assessing emotional wellbeing. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Emotional Well-being Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Emotional Well-being Scale includes 5 items assessing emotional wellbeing. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="60.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="56.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="60.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="56.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="60.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="56.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Social Functioning Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Social Functioning Scale includes 2 items assessing extent to which physical health or emotional problems interfere with normal social activities. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Social Functioning Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Social Functioning Scale includes 2 items assessing extent to which physical health or emotional problems interfere with normal social activities. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="50.0" upper_limit="87.5"/>
                    <measurement group_id="O2" value="62.5" lower_limit="50.0" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="50.0" upper_limit="87.5"/>
                    <measurement group_id="O2" value="62.5" lower_limit="50.0" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="50.0" upper_limit="87.5"/>
                    <measurement group_id="O2" value="62.5" lower_limit="37.5" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) Bodily Pain Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Bodily Pain Scale includes 2 items assessing the intensity of pain and effect of pain on normal work, both inside and outside the house. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) Bodily Pain Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The Bodily Pain Scale includes 2 items assessing the intensity of pain and effect of pain on normal work, both inside and outside the house. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="45.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="67.5" lower_limit="45.0" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="45.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="67.5" lower_limit="45.0" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="35.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="57.5" lower_limit="42.5" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-36) General Health Scale</title>
        <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The General Health Scale includes 4 items assessing personal evaluations of health. Items are transformed to a score with a range of 0-100.</description>
        <time_frame>1 year</time_frame>
        <population>Participants with SF-36 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Succinate</title>
            <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-36) General Health Scale</title>
          <description>Short Form Health Survey (SF-36) is a generic tool to assess overall health status and allows comparison between different diseases. Includes 8 multi-item scales with higher score indicating better health state. The General Health Scale includes 4 items assessing personal evaluations of health. Items are transformed to a score with a range of 0-100.</description>
          <population>Participants with SF-36 data available</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="25.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="40.0" lower_limit="25.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="25.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="35.0" lower_limit="25.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="25.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="35.0" lower_limit="25.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metoprolol Succinate</title>
          <description>Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).&#xD;
Metoprolol succinate: Extended release Metoprolol succinate</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo&#xD;
Placebo: Matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Chest Pain, not otherwise specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Head, eyes, ears, nose and throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections, non-pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma/Falls</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Other Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic, non-stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="72" subjects_affected="55" subjects_at_risk="268"/>
                <counts group_id="E2" events="47" subjects_affected="32" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Other Respiratory</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="268"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="268"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="268"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory Infections</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="268"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="205" subjects_affected="115" subjects_at_risk="268"/>
                <counts group_id="E2" events="209" subjects_affected="122" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="264"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Connett</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-9010</phone>
      <email>john-c@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

